Twist Bioscience Corporation financials

TWST CIK 0001581280

Source: EDGAR filings · Built 2026-06-02T04:14:29Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -75.63M -69.17M -170.25M -226.24M -139.31M -152.12M
EBITDA -111.41M -189.40M -187.85M -218.26M -142.98M -133.40M
Working Capital 241.56M 275.77M 350.93M 505.82M 483.44M 298.84M
Net Debt -107.48M -141.29M -192.40M -283.77M -402.91M -57.69M
Gross Margin 50.72% 42.61% 36.61% 41.38% 39.08% 31.85%
Operating Margin -36.18% -70.56% -88.60% -115.33% -115.41% -155.47%
Net Margin -20.63% -66.69% -83.48% -107.02% -114.94% -155.31%
Return on Equity (ROE) -16.42% -44.16% -32.82% -27.60% -26.19% -41.61%
Return on Assets (ROA) -12.10% -33.98% -26.35% -22.66% -21.66% -35.08%
Current Ratio 3.64× 4.88× 5.79× 6.58× 8.67× 9.29×
Debt-to-Equity 0.16× 0.18× 0.15× 0.12× 0.11× 0.11×
Effective Tax Rate -0.93% -0.27% -0.57% 4.56% 1.25% -0.27%
Cash Conversion Ratio 0.61× 0.31× 0.70× 0.57× 0.74× 1.02×
Accruals Ratio -0.05× -0.24× -0.08× -0.10× -0.06× 0.01×
SBC % of Revenue 17.12% 16.27% 12.35% 39.13% 27.96% 18.97%
CapEx Coverage -1.70× -12.63× -5.13× -1.22× -4.15× -14.42×
Free Cash Flow Per Share $-1.26 $-1.19 $-2.99 $-4.20 $-2.89 $-3.88

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 4.53× 8.50× 4.76× 9.78× 40.01× 38.01×
P/B 3.61× 5.63× 1.87× 2.52× 9.12× 10.19×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cost of Revenue 185.57M 179.63M 155.38M 119.33M 80.62M 61.41M
Research and Development Expense 80.28M 90.85M 106.89M 120.31M 69.07M 43.01M
Selling, General and Administrative Expense 246.98M 218.40M 189.74M 212.95M 135.90M 103.27M
Operating Income (Loss) -136.26M -220.83M -217.16M -234.78M -152.73M -140.08M
Income Tax Expense (Benefit) 719.00K 560.00K 1.15M -10.41M -1.93M 382.00K
Net Income (Loss) Attributable to Parent -77.67M -208.73M -204.62M -217.86M -152.10M -139.93M
Earnings Per Share, Basic $-1.30 $-3.60 $-3.60 $-4.04 $-3.15 $-3.57
Weighted Average Number of Shares Outstanding, Basic 59.81M 58.02M 56.88M 53.88M 48.25M 39.19M
Earnings Per Share, Diluted $-1.30 $-3.60 $-3.60 $-4.04 $-3.15 $-3.57
Weighted Average Number of Shares Outstanding, Diluted 59.81M 58.02M 56.88M 53.88M 48.25M 39.19M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 183.05M 226.32M 286.47M 378.69M 465.83M 93.67M
Assets, Current 332.97M 346.78M 424.26M 596.48M 546.50M 334.87M
Assets 641.86M 614.32M 776.40M 961.38M 702.10M 398.88M
Long-term Debt 4.17M
Liabilities, Current 91.41M 71.01M 73.32M 90.66M 63.05M 36.03M
Long-term Debt, Excluding Current Maturities 1.40M
Liabilities 168.90M 141.63M 152.97M 171.99M 121.28M 62.62M
Stockholders' Equity Attributable to Parent 472.96M 472.69M 623.43M 789.38M 580.82M 336.26M
Common Stock, Shares, Outstanding 60.63M 58.88M 57.56M 56.52M 49.50M 45.08M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -47.63M -64.09M -142.47M -124.39M -112.24M -142.25M
Payments to Acquire Property, Plant, and Equipment 28.00M 5.08M 27.78M 101.86M 27.06M 9.87M
Net Cash Provided by (Used in) Investing Activities -24.76M -3.07M 50.61M -232.93M 156.16M -114.65M
Net Cash Provided by (Used in) Financing Activities 28.54M 6.89M 911.00K 270.53M 329.18M 303.73M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TWST CIK 0001581280), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

VALU

VALUE LINE, INC.

DFTX

Definium Therapeutics, Inc.

MTW

MANITOWOC CO INC